- Home
- RETO vs BCAB Comparison
RETO vs BCAB Comparison
Compare RETO & BCAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RETO
- BCAB
- Stock Information
- Founded
- RETO 1999
- BCAB 2007
- Country
- RETO China
- BCAB United States
- Employees
- RETO N/A
- BCAB N/A
- Industry
- RETO Multi-Sector Companies
- BCAB Medicinal Chemicals and Botanical Products
- Sector
- RETO Consumer Discretionary
- BCAB Health Care
- Exchange
- RETO Nasdaq
- BCAB Nasdaq
- Market Cap
- RETO 24.7M
- BCAB 22.3M
- IPO Year
- RETO 2017
- BCAB 2020
- Fundamental
- Price
- RETO $2.09
- BCAB $0.38
- Analyst Decision
- RETO
- BCAB Buy
- Analyst Count
- RETO 0
- BCAB 2
- Target Price
- RETO N/A
- BCAB $1.00
- AVG Volume (30 Days)
- RETO 41.2K
- BCAB 633.4K
- Earning Date
- RETO 07-07-2025
- BCAB 08-07-2025
- Dividend Yield
- RETO N/A
- BCAB N/A
- EPS Growth
- RETO N/A
- BCAB N/A
- EPS
- RETO N/A
- BCAB N/A
- Revenue
- RETO $1,828,976.00
- BCAB $11,000,000.00
- Revenue This Year
- RETO N/A
- BCAB N/A
- Revenue Next Year
- RETO N/A
- BCAB N/A
- P/E Ratio
- RETO N/A
- BCAB N/A
- Revenue Growth
- RETO N/A
- BCAB N/A
- 52 Week Low
- RETO $1.91
- BCAB $0.24
- 52 Week High
- RETO $18.20
- BCAB $2.53
- Technical
- Relative Strength Index (RSI)
- RETO 29.05
- BCAB 43.16
- Support Level
- RETO $3.05
- BCAB $0.36
- Resistance Level
- RETO $3.15
- BCAB $0.43
- Average True Range (ATR)
- RETO 0.25
- BCAB 0.05
- MACD
- RETO -0.07
- BCAB -0.01
- Stochastic Oscillator
- RETO 31.45
- BCAB 11.48
About RETO ReTo Eco-Solutions Inc.
ReTo Eco-Solutions Inc is a manufacturer and distributor of eco-friendly construction materials and fly-ash, as well as equipment used to produce these eco-friendly construction materials. The company engaged in providing consultation, design, project implementation and construction of urban ecological environments for capturing, controlling and re-using rainwater. It operates through four segments namely Machinery and Equipment sales, Construction materials sales, Municipal Construction Projects, and Technology Consulting and other services. The company earns its revenue from Machinery and Equipment sales segment. Geographically, it derives a majority of its revenue from China.
About BCAB BioAtla Inc.
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.